Avalon GloboCare Corp (NASDAQ:AVCO) has received a notice of allowance from the US Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform.
The company’s QTY code is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development, the company said.
The patent was jointly filed with Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.
READ: Avalon GloboCare says its co-developed QTY code protein code technology featured in Chemical Reviews
“We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” Avalon CEO David Jin said in a statement.
“Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.”
Avalon also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This application was also filed with MIT’s Zhang. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy, the company said.
Avalon’s proprietary AVA-Trap technology utilizes artificial intelligence (AI) enhanced QTY code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as COVID-19 and cancer metastasis.
Avalon GloboCare is a clinical-stage celltech biodeveloper advancing innovative immune effector cell therapy and exosome technology.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel